文献速递前列腺癌

5α-还原酶抑制剂与前列腺癌死亡风险

5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
PubMed 文献 · J Urol · 2020-04-03

基于瑞典前列腺癌数据库89,227例患者,比较诊断前使用5α-还原酶抑制剂超过180天的5,816例与未使用者,按Gleason分级分组分析前列腺癌死亡风险。结果显示高危患者中各Gleason分级组风险均无显著差异,提示5α-还原酶抑制剂不影响Gleason分级与死亡风险的关联。

要点

  • 高危前列腺癌患者中,5α-还原酶抑制剂使用与否的死亡风险在各Gleason分级组均无显著差异
  • Gleason分级组1-5的HR分别为1.02、1.04、1.27、0.95、0.99,均无统计学意义
  • 5α-还原酶抑制剂不改变Gleason分级对前列腺癌死亡风险的预测价值

核心结论

  • 5α-还原酶抑制剂使用与前列腺癌死亡风险在各Gleason分级组中均无显著差异。

研究设计与样本

  • 使用Cox比例风险模型评估前列腺癌死亡风险比,调整年龄、合并症、教育程度和根治性治疗。

主要发现

  • 高危前列腺癌患者中,5α-还原酶抑制剂使用者与非使用者相比,Gleason分级组1的HR为1.02(95%CI 0.53-1.95)。
  • Gleason分级组2的HR为1.04(95%CI 0.65-1.69),组3为1.27(95%CI 0.89-1.80)。
  • Gleason分级组4的HR为0.95(95%CI 0.76-1.18),组5为0.99(95%CI 0.83-1.19)。

关键数值与推荐

  • 5α-还原酶抑制剂使用定义为诊断前使用超过180天。
  • 高危前列腺癌患者按Gleason分级组分层分析。

临床怎么用

  • 对于使用5α-还原酶抑制剂后诊断的前列腺癌患者,Gleason分级仍可用于风险分层,无需因用药史而调整对分级意义的判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 5α-Reductase inhibitors reduced the risk of prostate cancer in 25% in 2 randomized trials but increased the risk of Gleason 8-10 at biopsy. One explanation is that 5α-reductase inhibitors induce morphological changes in prostate cancer cells similar to higher Gleason grades but without its adverse biology. We compared risk of prostate cancer death between men on 5α-reductase inhibitors and men not on 5α-reductase inhibitors before prostate cancer diagnosis in each Gleason Grade Group. MATERIALS AND METHODS: Prostate Cancer data Base Sweden consists of linkages between the National Prostate Cancer Register, the Prescribed Drug Registry and the Cause of Death Registry. Of 89,227 men diagnosed with prostate cancer between July 2007 and December 2016, 5,816 had been on 5α-reductase inhibitors for more than 180 days before the date of diagnosis. Followup ended in December 2018. A Cox proportional hazard model was used to assess hazard ratio for prostate cancer death. Adjustments for age, comorbidity, education and curative treatment were made. Men with high risk cancer were stratified according to Gleason Grade Group. RESULTS: In men with high risk cancer the risk of prostate cancer death was similar among 5α-reductase inhibitor users and nonusers, with Gleason Grade Group 1 HR 1.02 (95% CI 0.53-1.95), Gleason Grade Group 2 HR 1.04 (95% CI 0.65-1.69), Gleason Grade Group 3 HR 1.27 (95% CI 0.89-1.80), Gleason Grade Group 4 HR 0.95 (95% CI 0.76-1.18) and Gleason Grade Group 5 HR 0.99 (95% CI 0.83-1.19), for 5α-reductase inhibitor users vs nonusers. CONCLUSIONS: We found no evidence that 5α-reductase inhibitors affect Gleason grading as no difference in mortality was observed among 5α-reductase inhibitor users and nonusers in each Gleason group.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bonde Miranda T, Garmo H, Stattin P, et al. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death. J Urol. 2020. PMID: 32243243. doi:10.1097/JU.0000000000001038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。